Search Results

Alnylam Pharmaceuticals, Inc. said that Chief Executive Officer Yvonne Greenstreet has been selected as the 2024 Woman of the Year by the Healthcare Businesswomen’s Association.

Horizon Therapeutics plc announced that Dara Mann, vice president, marketing, ophthalmology, has been named a 2022 Healthcare Businesswomen’s Association Rising Star.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Elizabeth H.Z. Thompson, Ph.D., executive vice president, research and development, has been named a 2021 Healthcare Businesswomen’s Association (HBA) Luminary. The HBA is the leading nonprofit global organization committed to furthering the advancement and impact of women in health c

In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh discuss the industry’s need to catch up with women’s health issues and the innovative lead the APAC region has taken in clinical trials.

DarioHealth Corp. (Nasdaq: DRIO) (“Dario” or the “Company”), a leader in the global digital health market, announced today the presentation of research at the American Diabetes Association 83rd Scientific Sessions (the “Scientific Sessions”) demonstrating significant reductions in HbA1c for Dario users compared to non-users.

Syneos Health®, the only fully integrated biopharmaceutical solutions organization, announced that Lynn Hamilton, Senior Director, Clinical Operations and Clinical Development Services, and Katya Magonova, MBA, Senior Engagement Manager, Commercial Advisory Group, have been recognized by the Healthcare Businesswomen’s Association as exemplary female leaders in the biopharmaceutical industry for 2021.

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa) today announced its sponsorship of the American Heart Association’s new Addressing Recurrent Pericarditis initiative, a multi-faceted effort to improve quality of care through identification, dissemination, and implementation of best practices for the diagnosis and management of recurrent pericarditis.

EVŌQ Nano announced its antimicrobial medical device platform has demonstrated effectiveness against the world’s leading pathogens implicated in healthcare-associated infections, which are some of the most common complications of hospital care.

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that results from the prevalence phase of its CATALYST study of hypercortisolism (Cushing’s syndrome) in patients with difficult-to-control type 2 diabetes were presented at the American Diabetes Association’s 84th Scientific Sessions.

OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, today announced new data for liver-targeted mitochondrial protonophore TLC-6740 being presented at the 84th Scientific Sessions of the American Diabetes Association being held June 21-24, 2024, in Orlando, Fla.